Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.50 |
| ▸ | BCHE | P06276 | 7/20 | 0.50 |
| ▸ | BACE1 | P56817 | 6/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885290 | 0.87 | BACE1 (0.64) | ACHEBCHEBACE1ALDH1A1 | |
| SCHEMBL13761943 | 0.87 | BACE1 (0.64) | ACHEBCHEBACE1ALDH1A1 | |
| SCHEMBL8259147 | 0.87 | BACE1 (0.64) | ACHEBCHEBACE1ALDH1A1 | |
| SCHEMBL13761638 | 0.85 | ALDH1A1 (0.60) | ACHEBCHEBACE1ALDH1A1 | |
| SCHEMBL3307906 | 0.83 | ACHE (0.62) | ACHEBCHEBACE1SIGMAR1ALDH1A1 | |
| SCHEMBL8259127 | 0.83 | FUCA1 (0.47) | ACHEBCHEBACE1FUCA1SIGMAR1 | |
| SCHEMBL8187685 | 0.80 | FUCA1 (0.55) | ACHEBCHEBACE1FUCA1SIGMAR1 | |
| SCHEMBL22593919 | 0.78 | FUCA1 (0.61) | ACHEFUCA1SIGMAR1ALDH1A1MC4R | |
| SCHEMBL1814808 | 0.77 | ACHE (0.55) | ACHEBCHEBACE1FUCA1SIGMAR1 | |
| SCHEMBL12384414 | 0.77 | FUCA1 (0.55) | ACHEBCHEBACE1FUCA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | ACHE 4800/4885BCHE 4721/4885BACE1 4659/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | ACHE 4630/4885BCHE 4727/4885BACE1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.